Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus

Lysette N. Broekhuizen; Bregtje A. Lemkes; H. L. Mooij; M. C. Meuwese; H.J. Verberne; F. Holleman; Reinier O. Schlingemann; M. Nieuwdorp; Erik S. G. Stroes; H. Vink

doi:10.1007/s00125-010-1910-x

Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus

Lysette N. Broekhuizen, Bregtje A. Lemkes, H. L. Mooij, M. C. Meuwese, H.J. Verberne, F. Holleman, Reinier O. Schlingemann, M. Nieuwdorp, Erik S. G. Stroes^*, H. Vink

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Aims/hypothesis Endothelial glycocalyx perturbation contributes to increased vascular permeability. In the present study we set out to evaluate whether: (1) glycocalyx is perturbed in individuals with type 2 diabetes mellitus, and (2) oral glycocalyx precursor treatment improves glycocalyx properties. Methods Male participants with type 2 diabetes (n=10) and controls (n=10) were evaluated before and after 2 months of sulodexide administration (200 mg/day). The glycocalyx dimension was estimated in two different vascular beds using sidestream dark field imaging and combined fluorescein/indocyanine green angiography for sublingual and retinal vessels, respectively. Transcapillary escape rate of albumin (TERalb) and hyaluronan catabolism were assessed as measures of vascular permeability. Results Both sublingual dimensions (0.64 [0.57-0.75] mu m vs 0.78 [0.71-0.85] mu m, p

Original language	English
Pages (from-to)	2646-2655
Journal	Diabetologia
Volume	53
Issue number	12
DOIs	https://doi.org/10.1007/s00125-010-1910-x
Publication status	Published - Dec 2010

Keywords

Diabetes mellitus type 2
Endothelial glycocalyx
Hyaluronan
Sulodexide
Vascular permeability

Access to Document

10.1007/s00125-010-1910-xLicence: CC BY-NC

Cite this

@article{5dfceda0e5c240948b4a4ac3ceadc061,

title = "Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus",

abstract = "Aims/hypothesis Endothelial glycocalyx perturbation contributes to increased vascular permeability. In the present study we set out to evaluate whether: (1) glycocalyx is perturbed in individuals with type 2 diabetes mellitus, and (2) oral glycocalyx precursor treatment improves glycocalyx properties. Methods Male participants with type 2 diabetes (n=10) and controls (n=10) were evaluated before and after 2 months of sulodexide administration (200 mg/day). The glycocalyx dimension was estimated in two different vascular beds using sidestream dark field imaging and combined fluorescein/indocyanine green angiography for sublingual and retinal vessels, respectively. Transcapillary escape rate of albumin (TERalb) and hyaluronan catabolism were assessed as measures of vascular permeability. Results Both sublingual dimensions (0.64 [0.57-0.75] mu m vs 0.78 [0.71-0.85] mu m, p",

keywords = "Diabetes mellitus type 2, Endothelial glycocalyx, Hyaluronan, Sulodexide, Vascular permeability",

author = "Broekhuizen, {Lysette N.} and Lemkes, {Bregtje A.} and Mooij, {H. L.} and Meuwese, {M. C.} and H.J. Verberne and F. Holleman and Schlingemann, {Reinier O.} and M. Nieuwdorp and Stroes, {Erik S. G.} and H. Vink",

year = "2010",

month = dec,

doi = "10.1007/s00125-010-1910-x",

language = "English",

volume = "53",

pages = "2646--2655",

journal = "Diabetologia",

issn = "0012-186X",

publisher = "Springer",

number = "12",

}

TY - JOUR

T1 - Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus

AU - Broekhuizen, Lysette N.

AU - Lemkes, Bregtje A.

AU - Mooij, H. L.

AU - Meuwese, M. C.

AU - Verberne, H.J.

AU - Holleman, F.

AU - Schlingemann, Reinier O.

AU - Nieuwdorp, M.

AU - Stroes, Erik S. G.

AU - Vink, H.

PY - 2010/12

Y1 - 2010/12

N2 - Aims/hypothesis Endothelial glycocalyx perturbation contributes to increased vascular permeability. In the present study we set out to evaluate whether: (1) glycocalyx is perturbed in individuals with type 2 diabetes mellitus, and (2) oral glycocalyx precursor treatment improves glycocalyx properties. Methods Male participants with type 2 diabetes (n=10) and controls (n=10) were evaluated before and after 2 months of sulodexide administration (200 mg/day). The glycocalyx dimension was estimated in two different vascular beds using sidestream dark field imaging and combined fluorescein/indocyanine green angiography for sublingual and retinal vessels, respectively. Transcapillary escape rate of albumin (TERalb) and hyaluronan catabolism were assessed as measures of vascular permeability. Results Both sublingual dimensions (0.64 [0.57-0.75] mu m vs 0.78 [0.71-0.85] mu m, p

AB - Aims/hypothesis Endothelial glycocalyx perturbation contributes to increased vascular permeability. In the present study we set out to evaluate whether: (1) glycocalyx is perturbed in individuals with type 2 diabetes mellitus, and (2) oral glycocalyx precursor treatment improves glycocalyx properties. Methods Male participants with type 2 diabetes (n=10) and controls (n=10) were evaluated before and after 2 months of sulodexide administration (200 mg/day). The glycocalyx dimension was estimated in two different vascular beds using sidestream dark field imaging and combined fluorescein/indocyanine green angiography for sublingual and retinal vessels, respectively. Transcapillary escape rate of albumin (TERalb) and hyaluronan catabolism were assessed as measures of vascular permeability. Results Both sublingual dimensions (0.64 [0.57-0.75] mu m vs 0.78 [0.71-0.85] mu m, p

KW - Diabetes mellitus type 2

KW - Endothelial glycocalyx

KW - Hyaluronan

KW - Sulodexide

KW - Vascular permeability

U2 - 10.1007/s00125-010-1910-x

DO - 10.1007/s00125-010-1910-x

M3 - Article

C2 - 20865240

SN - 0012-186X

VL - 53

SP - 2646

EP - 2655

JO - Diabetologia

JF - Diabetologia

IS - 12

ER -

Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus

Abstract

Keywords

Access to Document

Fingerprint

Cite this